Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2016 Publisher: Pfizer Limited, Ramsgate Road, Sandwich, CT13 9NJ, UK
Pharmacotherapeutic group: Progestogens – Pregnen (4) derivatives
ATC code: G03DA02
Medroxyprogesterone acetate has actions and uses similar to those of progesterone.
MPA has minimal androgenic activity compared to progesterone and virtually no oestrogenic activity.
Progestogens are used in the treatment of dysfunctional uterine bleeding, secondary amenorrhoea and endometriosis.
MPA is rapidly absorbed from the G-I tract with a single oral dose of 10-250 mg. The time taken to reach the peak serum concentration (Tmax) was 2-6 hours and the average peak serum concentration (Cmax) was 13-46.89 mg/ml.
Unmetabolised MPA is highly plasma protein bound. MPA is metabolised in the liver.
MPA is primarily metabolised by faecal excretion as glucuronide conjugated metabolite.
Metabolised MPA is excreted more rapidly and in a greater percentage following oral doses than after aqueous intramuscular injection.
None stated.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
